Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910373 | 0.96 | KMT2A (0.46) | MEN1KMT2ADPP7CTSC | |
| SCHEMBL29630487 | 0.96 | KMT2A (0.46) | MEN1KMT2ADPP7CTSC | |
| SCHEMBL29630484 | 0.94 | KMT2A (0.43) | MEN1KMT2ADPP7CTSCBMP1 | |
| SCHEMBL29376508 | 0.94 | MEN1 (0.47) | MEN1KMT2ADPP7FOLH1NAALAD2 | |
| SCHEMBL29413008 | 0.93 | FOLH1 (0.49) | MEN1KMT2ADPP7FOLH1 | |
| SCHEMBL30193330 | 0.92 | MEN1 (0.41) | MEN1KMT2ADPP7CTSCBMP1 | |
| SCHEMBL5970814 | 0.92 | KMT2A (0.49) | MEN1KMT2ADPP7CTSC | |
| SCHEMBL5970810 | 0.92 | KMT2A (0.49) | MEN1KMT2ADPP7CTSC | |
| SCHEMBL21647349 | 0.92 | KMT2A (0.49) | MEN1KMT2ADPP7CTSC | |
| SCHEMBL29630350 | 0.91 | MEN1 (0.41) | MEN1KMT2ADPP7CTSCBMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367169-A1 | FORMULATIONS FOR PERSONALIZED METHODS OF TREATMENT | FAETH THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12220402-B2 | Formulations for personalized methods of treatment | FAETH THERAPEUTICS, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. | 2023-03-23 | — | — | US | disclosed |
| US-20220117943-A1 | FORMULATIONS FOR PERSONALIZED METHODS OF TREATMENT | FAETH THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MEN1 1450/4885KMT2A 3707/4885DPP7 70/4885 |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MEN1 1450/4885KMT2A 3707/4885DPP7 70/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | MEN1 1450/4885KMT2A 3707/4885DPP7 70/4885 |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MEN1 1450/4885KMT2A 3707/4885DPP7 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.